E093 Real-life switching from infliximab innovator (Remicade) to biosimilar (Inflectra) in patients with various rheumatic diseases: a 6-month single-centre prospective observational study | Zendy

AI Assistant Blog Pricing

E093 Real-life switching from infliximab innovator (Remicade) to biosimilar (Inflectra) in patients with various rheumatic diseases: a 6-month single-centre prospective observational study

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.